Observed Signal · Nov 4, 2026 · Funding · Source: Tech.eu (European Tech & Deals) · Impact: 1/5 · Sentiment: Positive
bit.bio Raises $25M Series D for Cell Models
bit.bio, a human cell programming company, announced it has closed a $25 million Series D funding round. The investment will be used to expand its portfolio of human cell models and increase access to its technology for pharmaceutical, biotechnology, and research organizations. The round includes participation from existing investor M&G Investments and Dr Jonathan Milner, founder and former CEO of Abcam. The company's opti-ox™ platform enables the production of defined human cell types at scale, and its ioCells portfolio includes over 50 cell types for drug discovery and disease research. The funding comes as AI accelerates drug candidate identification and there is growing demand for alternatives to animal testing.
Funding round of a biotech company, not directly related to AdTech or digital marketing.
Track M&G Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- bit.bio closed a $25 million Series D funding round.
- The round includes participation from M&G Investments and Dr Jonathan Milner.
- bit.bio's opti-ox™ platform enables scalable production of defined human cell types.
- The ioCells portfolio includes over 50 human cell types.
- Funding will be used to expand cell model portfolio and commercial growth.
Connected Companies & Entities
1 Entity mapped“Existing investor participating in the Series D round.”
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Cellbox Solutions Raises €5M Series A for Biological Transport
German warm-chain logistics technology company Cellbox Solutions has completed the final closing of its Series A financing, bringing the total to €5 million. The company will use the funds to develop its business model and expand its offering to include integrated logistics solutions for sensitive biological materials. Following the first closing of approximately €3.5 million in March 2026, additional investors including members of Baltic Business Angels Invest GmbH participated, with existing investors NRW.BANK and Fraunhofer Venture also joining. Cellbox Solutions provides portable CO₂ incubator platforms for transporting living cells, organoids, and tissues under controlled physiological conditions. The company plans to expand rental and recurring service offerings, combine them with transportation and monitoring, and scale internationally. With over 400 systems on the market, the company aims to build longer-term customer relationships and a more scalable service model across markets.
Atlas Bio Raises $12.5M for AI Clinical Trial Simulations
Swiss biotech startup Atlas Bio emerged from stealth with a total of $12.5 million in funding to develop an AI foundation model for in-silico clinical trials. The Seed round of $10 million was led by Creandum, with participation from First Momentum Ventures and LEA Partners, who also led a previously undisclosed pre-Seed round of $2.5 million. The company's model, trained on 2 million human RNA readouts, simulates patient-level drug efficacy and safety, aiming to replace Phase II trials and animal testing. Atlas Bio is already working with a top-10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow. The founders, Simon Romanski and Sebastian Bayer, emphasize the potential to reduce drug development costs and timelines significantly.
Biolevate raises €30M Series A for life sciences AI
Biolevate, a Paris-based life sciences AI company, has raised €30 million in Series A funding to scale its enterprise agentic AI platform designed to automate scientific and regulatory workflows. The round was co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F, and existing investor EQT Ventures. The platform enables life sciences organizations to run thousands of concurrent AI agents, with outputs grounded in source evidence and human oversight, facilitating use in regulated environments. Since its 2024 seed round, Biolevate has expanded to over a dozen enterprise customers, achieving significant efficiency gains in literature reviews and regulatory intelligence. The company is opening a US office in Boston, has doubled headcount, and plans to double again, while also filing patents in Europe.
Receive all future signals for M&G & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.